A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults.

Trial Profile

A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs PF 5190457 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms MAD
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Sep 2016 Results assessing safety, pharmacokinetics and pharmacodynamics of SAD and MAD studies published in the British Journal of Clinical Pharmacology.
    • 16 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Planned end date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top